[ADMP] Adamis Pharmaceuticals Corporation


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 2.85 Change: 0.15 (5.56%)
Ext. hours: Change: 0 (0%)

chart ADMP

Refresh chart

Strongest Trends Summary For ADMP

ADMP is in the long-term down -51% below S&P in 10 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Adamis Pharmaceuticals Corporation, a biopharmaceutical company, is engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergies, oncology, and immunology. Its specialty pharmaceutical division has four products in its pipeline, including the Epinephrine Injection Pre-filled Syringe (PFS) for use in the emergency treatment of anaphylaxis; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease (COPD); and APC-3000, a hydrofluoroalkane (HFA) inhaled nasal steroid product for the treatment of allergic rhinitis. The company?s biotechnology division focuses on the development of therapeutic vaccine product candidates and cancer drugs for patients with unmet medical needs in the global cancer markets. Its four products under development include TeloB-VAX, a novel cell-based therapeutic cancer vaccine for prostate cancer; and three drugs comprise APC-100, APC-200, and APC-300 for

Fundamental Ratios
Shares Outstanding EPS-1.07 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-4.86
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-80.02% ROE-94.54% ROI
Current Ratio2.58 Quick Ratio Long Term Debt/Equity Debt Ratio0.18
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10.64 M Cash From Investing Activities Cash From Operating Activities-3.17 M Gross Profit
Net Profit-3.14 M Operating Profit-4.15 M Total Assets20.01 M Total Current Assets11.32 M
Total Current Liabilities2.28 M Total Debt Total Liabilities2.28 M Total Revenue
Technical Data
High 52 week5.75 Low 52 week2.55 Last close4.7 Last change8.05%
RSI83.33 Average true range0.28 Beta0.37 Volume88.65 K
Simple moving average 20 days22.68% Simple moving average 50 days26.53% Simple moving average 200 days8.69%
Performance Data
Performance Week23.68% Performance Month20.51% Performance Quart46.88% Performance Half9.3%
Performance Year25.33% Performance Year-to-date6.82% Volatility daily3.79% Volatility weekly8.48%
Volatility monthly17.39% Volatility yearly60.23% Relative Volume256.82% Average Volume686.06 K
New High New Low


2019-06-20 10:02:22 | Have Insiders Been Selling Adamis Pharmaceuticals Corporation NASDAQ:ADMP Shares?

2019-06-11 09:00:00 | Adamis Pharmaceuticals Provides Update on Its Higher Dose Naloxone Injection Product

2019-05-21 08:30:00 | Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product

2019-05-14 09:00:00 | Adamis Pharmaceuticals Announces Conditional Acceptance by FDA of Proprietary Name for Higher Dose Naloxone Product

2019-05-10 14:02:01 | Edited Transcript of ADMP earnings conference call or presentation 9-May-19 9:00pm GMT

2019-05-09 17:55:09 | Adamis Pharmaceuticals ADMP Reports Q1 Loss, Misses Revenue Estimates

2019-05-09 16:51:19 | Adamis: 1Q Earnings Snapshot

2019-05-09 16:30:00 | Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update

2019-05-07 09:00:00 | Adamis Pharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update

2019-05-02 10:32:02 | Adamis Pharmaceuticals ADMP May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2019-03-15 16:39:50 | Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update

2019-03-15 07:39:26 | The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA

2019-03-14 16:55:00 | Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate

2019-03-14 10:30:02 | Adamis Pharmaceuticals ADMP May Report Negative Earnings: Know the Trend Ahead of Q4 Release

2019-03-13 11:51:10 | Before You Buy Adamis Pharmaceuticals Corporation NASDAQ:ADMP, Consider Its Volatility

2019-02-27 08:13:48 | The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings

2019-02-26 18:54:40 | Adamis Provides Regulatory Update on Sublingual Tadalafil

2019-02-20 09:00:00 | Adamis Pharmaceuticals Publishes the Rationale for a Higher Dose Naloxone Product to Counter the Current Opioid Epidemic

2019-01-23 13:51:06 | Is Adamis Pharmaceuticals Corporation NASDAQ:ADMP Excessively Paying Its CEO?

2019-01-17 08:06:55 | The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US

2019-01-17 07:55:00 | Today's Research Reports on Trending Tickers: Adamis Pharmaceuticals and Biocept

2019-01-16 16:48:00 | Adamis stock surges on release of EpiPen alternative

2019-01-16 16:18:53 | Adamis’ Commercial Partner Launches SYMJEPI™ epinephrine in the US

2019-01-03 07:30:00 | Detailed Research: Economic Perspectives on Biohaven Pharmaceutical Holding, Air Transport Services Group, Pattern Energy Group, First Solar, Limelight Networks, and Adamis Pharmaceuticals — What Drives Growth in Today's Competitive Landscape

2019-01-02 10:21:43 | Adamis Has 'Favorable' Pipeline Setup, Says Bullish Raymond James

2018-12-31 16:02:21 | Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Naloxone Pre-Filled Syringe

2018-12-31 08:59:00 | 4 Pharma Stocks Gaining Speed on Monday 12/31/18

2018-12-28 19:46:50 | Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Tadalafil Sublingual Tablet

2018-12-21 08:53:01 | Adamis Pharmaceuticals ADMP Jumps: Stock Rises 5.3%

2018-12-17 09:00:02 | Implied Volatility Surging for Adamis Pharmaceuticals ADMP Stock Options

2018-12-06 19:19:49 | Novartis to launch Adamis' EpiPen rival in U.S. next year

2018-12-06 09:30:00 | Adamis Pharmaceuticals Provides Update on the U.S. Launch of SYMJEPI

2018-11-28 08:39:01 | Teva TEVA Launches First Generic Version of Mylan's EpiPen

2018-11-09 18:00:11 | Adamis Pharmaceuticals ADMP Reports Q3 Loss, Lags Revenue Estimates

2018-11-09 16:54:11 | Adamis: 3Q Earnings Snapshot

2018-11-09 16:46:06 | Adamis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Business Update

2018-11-06 10:30:03 | Adamis Pharmaceuticals ADMP May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2018-10-09 07:50:00 | Report: Developing Opportunities within Adamis Pharmaceuticals, Cass Information, Celldex Therapeutics, Par Pacific, Inovio Pharmaceuticals, and Liberty Global — Future Expectations, Projections Moving into 2018

2018-10-04 11:14:23 | Could Adamis Pharmaceuticals Corporation’s NASDAQ:ADMP Investor Composition Impacts Your Returns?

2018-09-27 16:05:00 | Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product

2018-09-27 08:35:12 | Adamis Pharmaceuticals ADMP in Focus: Stock Moves 8% Higher

2018-09-26 08:15:00 | Adamis Pharmaceuticals, FDA PDUFA Action Anticipated, Analyst Coverage

2018-09-25 08:57:12 | Options Traders Expect Huge Moves in Adamis Pharmaceuticals ADMP Stock

2018-09-25 08:37:12 | Implied Volatility Surging for Adamis Pharmaceuticals ADMP Stock Options

2018-08-27 12:02:03 | Adamis Pharmaceuticals Provides Business Update

2018-08-17 10:30:26 | Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead

2018-08-17 09:25:01 | Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen

2018-08-17 08:00:00 | Today’s Research Reports on Stocks to Watch: Antares Pharma and Adamis Pharmaceuticals

2018-08-16 17:02:46 | FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%

2018-08-16 13:25:00 | FDA approves first rival generic EpiPen, sending Teva shares up 6%